Akari Therapeutics (AKTX)

• Market cap: $22.3M
• 1 day: 5.81%
• 5 days: 8%
• 1 month: 47.24%
• 3 months: -27.59%
• 6 months: 14.7%
• Year to date: -1.12%
• 1 year: -60.72%
• 5 years: -99.2%
• 10 years: -99.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Employees: 5